Advancements in the Management of Gynecological Cancers: ESMO 2024 - Episode 6

Use of Trastuzumab Deruxtecan in Ovarian Cancer

, , , ,

Panelists discuss the recent tumor-agnostic approval of trastuzumab deruxtecan (T-DXd) based on findings from the DESTINY-PanTumor02 trial, its potential impact on treating advanced ovarian cancer given HER2 data, and how T-DXd may fit into the current treatment algorithm for ovarian cancer.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Approaching Biomarker Testing and Frontline Maintenance Therapy for Advanced Ovarian Cancer
    EP. 2: Key Findings from the PRIMA Trial: Niraparib in 1L Maintenance for Advanced Ovarian Cancer
    EP. 3: Duration of PARP Inhibitor Maintenance Therapy for Ovarian Cancer
    EP. 4: Emerging Combinations in Maintenance Therapy for Ovarian Cancer
    EP. 5: Optimizing Ovarian Cancer Care: PARP Resistance, Management of Oligoprogression, and Adverse Event Mitigation
    Now Viewing
    EP. 6: Use of Trastuzumab Deruxtecan in Ovarian Cancer
    EP. 7: Antibody-Drug Conjugates in Ovarian Cancer: Emerging Data and Treatment Integration
    EP. 8: Navigating Treatment Strategies for Advanced Cervical Cancer: Localized Therapy, KEYNOTE-A18 Trial Data, and Frontline Approaches
    EP. 9: Integrating Tisotumab Vedotin into Ovarian Cancer Therapy
    EP. 10: Biomarker Testing in Advanced Endometrial Cancer: Approach, Key Markers, and Impact on Treatment Decisions
    EP. 11: Managing Recurrent Endometrial Cancer: Treatment Strategies and RUBY Trial Insights
    EP. 12: Durvalumab in Endometrial Cancer: DUO-E Trial Updates
    EP. 13: Innovative Combination Strategies for Endometrial Cancer: Updates from LEAP and KEYNOTE-B21 Trials
    EP. 14: T-DXd in Advanced Endometrial Cancer
    EP. 15: Emerging ADCs in Advanced Endometrial Cancer: Anti-TROP2 and Anti-FR Agents

    Video content above is prompted by the following:

    • Briefly comment on the recent tumor agnostic approval for trastuzumab deruxtecan (T-DXd) based on the findings from DESTINY-PanTumor02.
    • Based on available HER2 data in ovarian cancer, what impact will this have on the treatment of advanced ovarian cancer?
    • Where do you see T-DXd fitting in your treatment algorithm for ovarian cancer?
    x